These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28632203)

  • 1. Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease.
    Janel N; Alexopoulos P; Badel A; Lamari F; Camproux AC; Lagarde J; Simon S; Feraudet-Tarisse C; Lamourette P; Arbones M; Paul JL; Dubois B; Potier MC; Sarazin M; Delabar JM
    Transl Psychiatry; 2017 Jun; 7(6):e1154. PubMed ID: 28632203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma DYRK1A as a novel risk factor for Alzheimer's disease.
    Janel N; Sarazin M; Corlier F; Corne H; de Souza LC; Hamelin L; Aka A; Lagarde J; Blehaut H; Hindié V; Rain JC; Arbones ML; Dubois B; Potier MC; Bottlaender M; Delabar JM
    Transl Psychiatry; 2014 Aug; 4(8):e425. PubMed ID: 25116835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.
    Dowjat K; Adayev T; Wojda U; Brzozowska K; Barczak A; Gabryelewicz T; Hwang YW
    J Alzheimers Dis; 2019; 72(4):1059-1075. PubMed ID: 31683476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from MCI to AD in patients with the APOE ε4 genotype: Prediction by plasma HCY and serum BDNF.
    Zheng L; Kong X; Cui Y; Wei Y; Zhang J; Wei W
    Neurosci Lett; 2016 Jul; 626():19-24. PubMed ID: 27180036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application value of serum biomarkers for choosing memantine therapy for moderate AD.
    Wei H; Zhu X; Li Y
    J Neurol; 2018 Aug; 265(8):1844-1849. PubMed ID: 29948244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Environmental Correlates of Serum BDNF: A Descriptive Study with Plausible Implications for AD Research.
    Weinstein G; Preis SR; Beiser AS; Kaess B; Chen TC; Satizabal C; Rahman F; Benjamin EJ; Vasan RS; Seshadri S
    Curr Alzheimer Res; 2017; 14(7):722-730. PubMed ID: 28164772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
    Kimura R; Kamino K; Yamamoto M; Nuripa A; Kida T; Kazui H; Hashimoto R; Tanaka T; Kudo T; Yamagata H; Tabara Y; Miki T; Akatsu H; Kosaka K; Funakoshi E; Nishitomi K; Sakaguchi G; Kato A; Hattori H; Uema T; Takeda M
    Hum Mol Genet; 2007 Jan; 16(1):15-23. PubMed ID: 17135279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte-specific Dyrk1a gene transfer rescues plasma apolipoprotein A-I levels and aortic Akt/GSK3 pathways in hyperhomocysteinemic mice.
    Tlili A; Jacobs F; de Koning L; Mohamed S; Bui LC; Dairou J; Belin N; Ducros V; Dubois T; Paul JL; Delabar JM; De Geest B; Janel N
    Biochim Biophys Acta; 2013 Jun; 1832(6):718-28. PubMed ID: 23429073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase.
    Noll C; Planque C; Ripoll C; Guedj F; Diez A; Ducros V; Belin N; Duchon A; Paul JL; Badel A; de Freminville B; Grattau Y; Bléhaut H; Herault Y; Janel N; Delabar JM
    PLoS One; 2009 Oct; 4(10):e7540. PubMed ID: 19844572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease.
    Ryu YS; Park SY; Jung MS; Yoon SH; Kwen MY; Lee SY; Choi SH; Radnaabazar C; Kim MK; Kim H; Kim K; Song WJ; Chung SH
    J Neurochem; 2010 Nov; 115(3):574-84. PubMed ID: 20456003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression.
    Pláteník J; Fišar Z; Buchal R; Jirák R; Kitzlerová E; Zvěřová M; Raboch J
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Apr; 50():83-93. PubMed ID: 24334212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral leukocyte expression of the potential biomarker proteins Bdnf, Sirt1, and Psen1 is not regulated by promoter methylation in Alzheimer's disease patients.
    Carboni L; Lattanzio F; Candeletti S; Porcellini E; Raschi E; Licastro F; Romualdi P
    Neurosci Lett; 2015 Sep; 605():44-8. PubMed ID: 26275347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BDNF and DYRK1A are variable and inversely correlated in lymphoblastoid cell lines from Down syndrome patients.
    Tlili A; Hoischen A; Ripoll C; Benabou E; Badel A; Ronan A; Touraine R; Grattau Y; Stora S; van Bon B; de Vries B; Menten B; Bockaert N; Gecz J; Antonarakis SE; Campion D; Potier MC; Bléhaut H; Delabar JM; Janel N
    Mol Neurobiol; 2012 Oct; 46(2):297-303. PubMed ID: 22669612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute aerobic exercise increases brain-derived neurotrophic factor levels in elderly with Alzheimer's disease.
    Coelho FG; Vital TM; Stein AM; Arantes FJ; Rueda AV; Camarini R; Teodorov E; Santos-Galduróz RF
    J Alzheimers Dis; 2014; 39(2):401-8. PubMed ID: 24164734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain-derived neurotrophic factor levels in Alzheimer's disease.
    O'Bryant SE; Hobson V; Hall JR; Waring SC; Chan W; Massman P; Lacritz L; Cullum CM; Diaz-Arrastia R;
    J Alzheimers Dis; 2009; 17(2):337-41. PubMed ID: 19363274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma homocysteine levels are not increased in murine models of Alzheimer's disease.
    Santiard-Baron D; Aupetit J; Janel N
    Neurosci Res; 2005 Dec; 53(4):447-9. PubMed ID: 16213620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic utility of VEGF and soluble CD40L levels in serum of Alzheimer's patients.
    Yu S; Liu YP; Liu YH; Jiao SS; Liu L; Wang YJ; Fu WL
    Clin Chim Acta; 2016 Jan; 453():154-9. PubMed ID: 26706786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.